|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrari P, Jenab M, Norat T, Moskal A,
Slimani N, Olsen A, Tjønneland A, Overvad K, Jensen MK,
Boutron-Ruault MC, et al: Lifetime and baseline alcohol intake and
risk of colon and rectal cancers in the European prospective
investigation into cancer and nutrition (EPIC). Int J Cancer.
121:2065–2072. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, et al: Annual report to the nation on the status of
cancer, 1975–2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening, and treatment) to reduce
future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar
|
|
5
|
Bosetti C, Levi F, Rosato V, Bertuccio P,
Lucchini F, Negri E and La Vecchia C: Recent trends in colorectal
cancer mortality in Europe. Int J Cancer. 129:180–191. 2011.
View Article : Google Scholar
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and downregulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar
|
|
8
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh SR and Rameshwar P: MicroRNA in
Development and in the Progression of Cancer. Springer; New York,
NY: 2014, View Article : Google Scholar
|
|
11
|
Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X,
Yu L, Wang L, Wang J, Wu Y, et al: A plasma microRNA panel for
early detection of colorectal cancer. Int J Cancer. 136:152–161.
2015. View Article : Google Scholar
|
|
12
|
Wang L, Tang H, Thayanithy V, Subramanian
S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ and Thibodeau SN:
Gene networks and microRNAs implicated in aggressive prostate
cancer. Cancer Res. 69:9490–9497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zanette DL, Rivadavia F, Molfetta GA,
Barbuzano FG, Proto-Siqueira R, Silva-Jr WA, Falcão RP and Zago MA:
miRNA expression profiles in chronic lymphocytic and acute
lymphocytic leukemia. Braz J Med Biol Res. 40:1435–1440. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nymark P, Guled M, Borze I, Faisal A,
Lahti L, Salmenkivi K, Kettunen E, Anttila S and Knuutila S:
Integrative analysis of microRNA, mRNA and aCGH data reveals
asbestos- and histology-related changes in lung cancer. Genes
Chromosomes. Cancer. 50:585–597. 2011.
|
|
15
|
Epis MR, Giles KM, Candy PA, Webster RJ
and Leedman PJ: miR-331-3p regulates expression of neuropilin-2 in
glioblastoma. J Neurooncol. 116:67–75. 2014. View Article : Google Scholar :
|
|
16
|
Guo X, Guo L, Ji J, Zhang J, Zhang J, Chen
X, Cai Q, Li J, Gu Q, Liu B, et al: miRNA-331-3p directly targets
E2F1 and induces growth arrest in human gastric cancer. Biochem
Biophys Res Commun. 398:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Epis MR, Giles KM, Kalinowski FC, Barker
A, Cohen RJ and Leedman PJ: Regulation of expression of
deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the
activation of eIF5A, by miR-331-3p and miR-642-5p in prostate
cancer cells. J Biol Chem. 287:35251–35259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Epis MR, Giles KM, Barker A, Kendrick TS
and Leedman PJ: miR-331-3p regulates ERBB-2 expression and androgen
receptor signaling in prostate cancer. J Biol Chem.
284:24696–24704. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kruser TJ and Wheeler DL: Mechanisms of
resistance to HER family targeting antibodies. Exp Cell Res.
316:1083–1100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mass RD: The HER receptor family: A rich
target for therapeutic development. Int J Radiat Oncol Biol Phys.
58:932–940. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Holbro T and Hynes NE: ErbB receptors:
Directing key signaling networks throughout life. Annu Rev
Pharmacol Toxicol. 44:195–217. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marmor MD, Skaria KB and Yarden Y: Signal
transduction and oncogenesis by ErbB/HER receptors. Int J Radiat
Oncol Biol Phys. 58:903–913. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu D and Hung MC: Overexpression of ErbB2
in cancer and ErbB2-targeting strategies. Oncogene. 19:6115–6121.
2000. View Article : Google Scholar
|
|
25
|
Tan M, Yao J and Yu D: Overexpression of
the c-erbB-2 gene enhanced intrinsic metastasis potential in human
breast cancer cells without increasing their transformation
abilities. Cancer Res. 57:1199–1205. 1997.PubMed/NCBI
|
|
26
|
Yu D, Jing T, Liu B, Yao J, Tan M,
McDonnell TJ and Hung MC: Overexpression of ErbB2 blocks
Taxol-induced apoptosis by upregulation of p21Cip1,
which inhibits p34Cdc2 kinase. Mol Cell. 2:581–591.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blok EJ, Kuppen PJ, van Leeuwen JE and
Sier CF: Cytoplasmic overexpression of HER2: A key factor in
colorectal cancer. Clin Med Insights Oncol. 7:41–51. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li SS, Buchbinder E, Wu L, Bjorge JD,
Fujita DJ and Zhu S: EGFR and HER2 levels are frequently elevated
in colon cancer cells. Discoveries Rep. 1:e12014. View Article : Google Scholar
|
|
30
|
Hynes NE and MacDonald G: ErbB receptors
and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nahta R and O'Regan RM: Evolving
strategies for overcoming resistance to HER2-directed therapy:
Targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer. 10(Suppl
3): S72–S78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Citri A and Yarden Y: EGF-ERBB signalling:
Towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Motoyama K, Inoue H, Takatsuno Y, Tanaka
F, Mimori K, Uetake H, Sugihara K and Mori M: Over- and
under-expressed microRNAs in human colorectal cancer. Int J Oncol.
34:1069–1075. 2009.PubMed/NCBI
|
|
35
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Epis MR, Barker A, Giles KM, Beveridge DJ
and Leedman PJ: The RNA-binding protein HuR opposes the repression
of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer
cells. J Biol Chem. 286:41442–41454. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang RM, Yang H, Fang F, Xu JF and Yang
LY: MicroRNA-331-3p promotes proliferation and metastasis of
hepatocellular carcinoma by targeting PH domain and leucine-rich
repeat protein phosphatase. Hepatology. 60:1251–1263. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kafi SG, Lari S and Nassiri G: HER2/neu
expression in colon adenocarcinoma and its correlation with
clinicopathologic variables. IJBMS. 9:64–69. 2006.
|
|
40
|
Kim SY, Kim HP, Kim YJ, Oh Y, Im SA, Lee
D, Jong HS, Kim TY and Bang YJ: Trastuzumab inhibits the growth of
human gastric cancer cell lines with HER2 amplification
synergistically with cisplatin. Int J Oncol. 32:89–95. 2008.
|
|
41
|
Mebratu Y and Tesfaigzi Y: How ERK1/2
activation controls cell proliferation and cell death: Is
subcellular localization the answer? Cell Cycle. 8:1168–1175. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ross JS and McKenna BJ: The HER-2/neu
oncogene in tumors of the gastrointestinal tract. Cancer Invest.
19:554–568. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
